Docetaxel

• Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; P… Ended
  2023-510159-53-01 Phase II 4 countries Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended
  2023-509923-42-00 Phase II 5 countries Medica Scientia Innovation Research S.L.
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun… Ended
  2023-505981-26-00 Phase III 9 countries F. Hoffmann-La Roche AG
• Phase III trial of laryngeal preservation comparating chemotherapy followed by radiotherapy to chemotherapy administrated during radiotherap… Ended
  2024-513976-16-00 Phase III 1 country Groupe Oncologie Radiotherapie Tete Cou
• PREDIX HER2 - preoperative treatment of HER2 positive breast cancer Ended
  2023-508411-23-00 Phase II 1 country Karolinska University Hospital
• "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended
  2024-515368-29-00 Phase III 1 country Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive N… Ended
  2024-516801-22-00 Phase III 1 country Cancer Trials Ireland
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended
  2024-516996-34-00 Phase III 2 countries Unicancer
• Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non… Halted
  2023-510082-10-00 Phase III 9 countries Novartis Pharma AG
• Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended
  2024-516299-13-00 Phase II 1 country Centre Francois Baclesse
• SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal car… Ended
  2024-516005-23-00 Phase II 1 country Centre Hospitalier Regional Universitaire
• A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended
  2022-502982-49-00 Phase II 5 countries Macrogenics Inc.
• A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer Ended
  2022-503108-26-00 Phase I (FiH) 3 countries Bristol-Myers Squibb Services Unlimited Company
• A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian… Ended
  2023-505005-16-00 Phase II 4 countries Merck Sharp & Dohme LLC
• A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Ended
  2024-511999-32-00 Phase I/II 2 countries Affimed GmbH
• 7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended
  2023-505284-36-00 Phase II 6 countries Merck Sharp & Dohme LLC
• A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local… Ended
  2024-513870-23-00 Phase III 8 countries Gilead Sciences Inc.
• MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non… Ended
  2022-501252-28-00 Phase II 9 countries Merck Sharp & Dohme LLC
• Randomized trial evaluating adapted chemotherapy in patients with squamous carcinoma Ended
  2024-512456-38-00 Phase II 1 country Groupe Oncologie Radiotherapie Tete Cou
• A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small C… Ended
  2024-516598-60-00 Phase III 3 countries Mirati Therapeutics Inc.
• Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended
  2022-500820-31-00 Phase II 6 countries Merck Sharp & Dohme LLC
• RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of t… Ended
  2024-516271-32-00 Phase III 1 country Universitat Heidelberg
• Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study) Ended
  2024-515532-72-00 Phase II 1 country Centre Hospitalier Regional De Marseille
• ABCSG 45: A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin… Ended
  2024-512821-10-00 Phase II 1 country Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And…

Showing 97–120 of 128 trials